Generate Biomedicines, Inc. (GENB) Valuation | Quantisight AI

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-546.2%

-$58.95

vs $13.21 price

Levered DCF

-$160.08

After debt service

Piotroski score

—

Altman Z-score

—

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024
P/E	-2.54×	-7.53×
P/B	-1.03×	-3.71×
P/S	19.87×	78.8×
EV / EBITDA	-2.78×	-9.24×
Gross margin	100.0%	100.0%
Operating margin	-737.0%	-962.6%
Net margin	-637.0%	-849.4%
Current ratio	2.85×	4.7×
Debt / equity	-0.11×	-0.18×
Interest coverage	-206.92×	-92.98×
Dividend yield	0.0%	0.0%
Payout ratio	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024
Return on equity	33.0%	40.0%
Return on invested capital	-89.4%	-43.9%
Return on assets	-61.5%	-33.5%
Free cash flow yield	-32.2%	-7.5%
Earnings yield	-32.1%	-10.8%
Enterprise value	$580.5M	$1.5B
Net debt / EBITDA	0.25×	0.61×
Cash conversion cycle (days)	0	5